Abstract
To assess dose proportionality of etoricoxib across the anticipated clinical dose range, a single panel of 12 healthy subjects was administered single oral doses of etoricoxib of 5, 10, 20, 40, and 120 mg in an open, two-part, five-period crossover study. Plasma samples were collected aftereach dose and analyzed for etoricoxib concentrations. The pharmacokinetics of etoricoxib appear to be linear over the entire dose range examined, from 5 to 120 mg. Etoricoxib was found to be well tolerated across the 5 to 120 mg dose range.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Adult
-
Analysis of Variance
-
Area Under Curve
-
Cross-Over Studies
-
Cyclooxygenase 2
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors / administration & dosage*
-
Cyclooxygenase Inhibitors / adverse effects
-
Cyclooxygenase Inhibitors / blood
-
Dose-Response Relationship, Drug
-
Etoricoxib
-
Female
-
Humans
-
Isoenzymes / antagonists & inhibitors*
-
Male
-
Membrane Proteins
-
Prostaglandin-Endoperoxide Synthases
-
Pyridines / administration & dosage*
-
Pyridines / adverse effects
-
Pyridines / blood
-
Sulfones / administration & dosage*
-
Sulfones / adverse effects
-
Sulfones / blood
Substances
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors
-
Isoenzymes
-
Membrane Proteins
-
Pyridines
-
Sulfones
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
Prostaglandin-Endoperoxide Synthases
-
Etoricoxib